The role of the proteasome in AML

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells

(2015) M. P. Martelli et al.   BLOOD

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells

(2015) C. Larrue et al.   BLOOD

Effective targeting of primitive AML CD34+cells by the second-generation proteasome inhibitor carfilzomib

(2015) Lieke H. van der Helm et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models

(2015) Fernando F. Corrales-Medina et al.   LEUKEMIA RESEARCH

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

(2015) Tadeusz Robak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

(2015) Jia Ruan et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells

(2015) Hiroaki Kimura et al.   Journal of Immunology Research

Association of an LMP2 Polymorphism with Acute Myeloid Leukemia and Multiple Myeloma

(2014) Filiz Ozbas-Gerceker et al.   Asian Pacific Journal of Cancer Prevention

Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity

(2014) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group

(2014) Terzah M. Horton et al.   PEDIATRIC BLOOD & CANCER

Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease

(2013) K. M. Bernot et al.   BLOOD

AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model

(2013) M. Wunderlich et al.   BLOOD

Inhibitors of the Immunoproteasome: Current Status and Future Directions

(2013) Zachary Miller et al.   CURRENT PHARMACEUTICAL DESIGN

Bortezomib sensitivity of acute myeloid leukemia CD34+ cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1

(2013) Matthieu Cornelis Johannes Bosman et al.   EXPERIMENTAL HEMATOLOGY

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

(2013) D. Niewerth et al.   HAEMATOLOGICA

Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity

(2013) E D Warlick et al.   LEUKEMIA

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

(2013) Alison R. Walker et al.   LEUKEMIA & LYMPHOMA

A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia

(2013) Dianna S. Howard et al.   LEUKEMIA RESEARCH

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

(2013) Eyal C. Attar et al.   LEUKEMIA RESEARCH

Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development

(2012) Eva Maria Huber et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

(2012) W. Blum et al.   BLOOD

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

(2012) J. Fang et al.   BLOOD

Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways

(2012) Xue-Jie Jiang et al.   CANCER LETTERS

Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity

(2012) Eva M. Huber et al.   CELL

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

(2012) Eyal C. Attar et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells

(2012) Danian Nie et al.   LEUKEMIA & LYMPHOMA

Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

(2012) Alison R. Walker et al.   LEUKEMIA & LYMPHOMA

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

(2012) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells

(2011) Ai-Hua Wang et al.   ANNALS OF HEMATOLOGY

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

(2011) J. W. Friedberg et al.   BLOOD

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim

(2011) Yun Dai et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

(2011) Nathan Fowler et al.   JOURNAL OF CLINICAL ONCOLOGY

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia

(2010) Shujun Liu et al.   CANCER CELL

Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy

(2010) Nagathihalli S Nagaraj et al.   Expert Review of Proteomics

Ubiquitin–proteasome system profiling in acute leukemias and its clinical relevance

(2010) Wanlong Ma et al.   LEUKEMIA RESEARCH

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with the proteasome status

(2009) Mariette Matondo et al.   LEUKEMIA RESEARCH

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

(2008) Pascale Flandrin et al.   CELL STRESS & CHAPERONES

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

(2008) E. C. Attar et al.   CLINICAL CANCER RESEARCH

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

(2008) E. Colado et al.   HAEMATOLOGICA